Drug class
Recombinant human acid alpha-glucosidase; enzyme replacement therapy biologic
Mechanism of action
Replaces deficient lysosomal acid alpha-glucosidase (GAA), enabling lysosomal hydrolysis of glycogen to glucose. The product is used with miglustat, which helps stabilise the enzyme and support cellular uptake.
General use cases
- Long-term enzyme replacement therapy in adults with late-onset Pompe disease (GAA deficiency), in combination with miglustat, under the applicable product authorisation
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
